212 related articles for article (PubMed ID: 21304937)
1. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.
Krishnan SM; Dixit NM
PLoS Comput Biol; 2011 Feb; 7(2):e1001072. PubMed ID: 21304937
[TBL] [Abstract][Full Text] [Related]
2. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
[TBL] [Abstract][Full Text] [Related]
3. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
Falasca K; Ucciferri C; Mancino P; Gorgoretti V; Pizzigallo E; Vecchiet J
J Med Virol; 2010 Jan; 82(1):49-56. PubMed ID: 19950239
[TBL] [Abstract][Full Text] [Related]
4. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
Devine EB; Kowdley KV; Veenstra DL; Sullivan SD
Value Health; 2001; 4(5):376-84. PubMed ID: 11705128
[TBL] [Abstract][Full Text] [Related]
5. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
Reau N; Hadziyannis SJ; Messinger D; Fried MW; Jensen DM
Am J Gastroenterol; 2008 Aug; 103(8):1981-8. PubMed ID: 18796095
[TBL] [Abstract][Full Text] [Related]
6. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
7. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Rivkin AM; Chawla S
Pharmacotherapy; 2005 Jun; 25(6):862-75. PubMed ID: 15927905
[TBL] [Abstract][Full Text] [Related]
9. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
11. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
Bertino G; Ardiri A; Boemi PM; Calvagno GS; Ruggeri IM; Speranza A; Santonocito MM; Ierna D; Bruno CM; Valenti M; Boemi R; Naimo S; Neri S
Eur J Clin Pharmacol; 2010 Oct; 66(10):1055-63. PubMed ID: 20652232
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
[TBL] [Abstract][Full Text] [Related]
14. Should ribavirin be used to treat hepatitis C in dialysis patients?
Carrion AF; Fabrizi F; Martin P
Semin Dial; 2011; 24(3):272-4. PubMed ID: 21480995
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Bräu N
J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
[TBL] [Abstract][Full Text] [Related]
17. Definition and management of anemia in patients infected with hepatitis C virus.
McHutchison JG; Manns MP; Longo DL
Liver Int; 2006 May; 26(4):389-98. PubMed ID: 16629641
[TBL] [Abstract][Full Text] [Related]
18. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
[TBL] [Abstract][Full Text] [Related]
19. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
[TBL] [Abstract][Full Text] [Related]
20. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]